Medizinische Hochschule Hannover
Hanover, Germany
Not recruitingOtorhinolaryngological surgery
Study on VSF1.01 for Reducing Surgery Trauma in Hearing Loss Patients Receiving Cochlear Implants
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
What is this trial about?
A plain-language summary of the goals, design and what participants do
This clinical trial is focused on studying the effects of a new treatment for people with hearing loss who are undergoing cochlear implant surgery. The treatment being tested is called VSF1.01, which is a solution for injection derived from the conditioned medium of adult human umbilical cord-derived mesenchymal stromal cells. The purpose of the study is to evaluate the safety of injecting VSF1.01 directly into the cochlea, which is the part of the inner ear involved in hearing, during the cochlear implant procedure.
Participants in the study will receive an injection of VSF1.01 during their cochlear implant surgery. The study will monitor the safety of this treatment by recording any adverse events, which are unexpected medical problems that may occur during the study. The study will also assess the health of the auditory nerve, which is responsible for transmitting sound signals to the brain, and evaluate speech perception in both quiet and noisy environments. Additionally, hearing thresholds will be measured using a method called pure tone audiometry, and the impedance levels of the electrode contacts will be checked to ensure they are functioning properly.
This study aims to provide valuable information about the safety of using VSF1.01 as an additional treatment during cochlear implant surgery. The findings could potentially lead to improved outcomes for individuals with hearing loss who are candidates for cochlear implants. The study is expected to continue until June 2026, with recruitment starting in September 2024.
The research process
The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.
Who can join the trial?
11 criteria
- Men, women, and individuals of diverse gender identities who are 18 years or older.
- Women who cannot have children due to:
- Having had surgery to prevent pregnancy, such as removal of ovaries or fallopian tubes.
- Having had a hysterectomy (removal of the uterus) or being born without a uterus.
- Being 50 years or older and having gone through menopause for more than a year.
- Women who can have children must:
- Practice sexual abstinence (not having sex) or have sex only with female partners or sterile male partners.
- If sexually active with a fertile male partner, have a negative pregnancy test during screening and agree to use reliable birth control methods until the end of the study. Acceptable methods include:
- Combined hormonal birth control (pills, patches, or rings) that stop ovulation.
- Progestogen-only hormonal birth control (pills, injections, implants) that stop ovulation.
- Intrauterine device (IUD).
- Intrauterine hormone-releasing system (IUS).
- Must provide signed written consent, showing they understand the study and agree to participate.
- Must have profound hearing loss (very severe hearing loss) and be a candidate for a cochlear implant. This includes those with or without some remaining hearing at low frequencies (measured in Hertz, Hz).
Who cannot join the trial?
3 criteria
- Patients who do not have hearing loss cannot participate.
- Patients who are not in the age range of 3 to 4 years old cannot participate.
- Patients who are part of a vulnerable population cannot participate. A vulnerable population includes groups like children, pregnant women, or people with certain disabilities who might need special protection in research.
Clinical Trials Concierge
Prefer not to search? Our Concierge searches the trials for you.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
Verified sites
All sites with verified contact details – recruitment status may not be available; ask directly
Verified
Trial locations
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingNot finding your country?
Not sure what to do next?
Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Investigated drugs
VSF1.01 is a special treatment being tested in this clinical trial. It is a mixture that contains tiny particles called extracellular vesicles, which are taken from human umbilical cord stem cells. These particles are thought to help reduce damage during cochlear implant surgery. The goal of using VSF1.01 is to make the surgery safer by protecting the delicate structures inside the ear. This treatment is given directly into the cochlea, which is the part of the ear that helps with hearing. The study is focused on making sure that this treatment is safe for patients who are getting cochlear implants.
What is already known about the treatment
VSF1.01 – VSF1.01 is administered directly into the cochlea, the part of the inner ear responsible for hearing, during cochlear implant surgery. It is currently being studied in a phase I/IIa clinical trial to assess its safety when used as an additional treatment for patients undergoing this type of surgery. The main therapeutic indication for VSF1.01 is to reduce trauma related to cochlear implant surgery, potentially improving outcomes for individuals with hearing loss. At the molecular level, VSF1.01 is enriched with extracellular vesicles derived from human umbilical cord mesenchymal stem cells, which are thought to aid in tissue repair and reduce inflammation. This medication falls under the pharmacological classification of regenerative medicine products.
Investigated diseases
Hearing Loss – Hearing loss is a condition where an individual experiences a reduced ability to hear sounds. It can occur in one or both ears and can be temporary or permanent. The progression of hearing loss can vary; it may happen suddenly or gradually over time. Causes include damage to the inner ear, buildup of earwax, infections, or exposure to loud noise. As the condition progresses, individuals may find it increasingly difficult to understand speech, especially in noisy environments. Hearing loss can affect people of all ages and may lead to social withdrawal and communication difficulties.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase I/IITrial ID2024-512498-29-00Protocol codeESCRTEstimated enrolment11 patientsSponsorMedizinische Hochschule Hannover
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?